EGFR and neoplasm: For example, NSCLC patients with EGFR mutation showed an unfavorable response to PD-L1/PD-1 inhibitors compared to those with wild-type EGFR, which could be related to the low TMB of EGFR-mutant tumor and an immunosuppressive TME (Dong et al., 2017b).